Engineered EPHB4-CAR-T cells showed sustained killing activity against osteosarcoma as well as against rhabdomyosarcoma cell lines, even for PAX3-FOXO1-positive ARMS cells, which exhibit highly malignant immunomodulatory effects [38]. Here, EPHB4 is linked to rhabdomyosarcoma.